Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S. New Phase 2 study to...
Updated data from Phase 2 study show confirmed objective response rate of 52% and 36-month progression-free survival rate of 79% with nearly 40 months of follow-up New Phase 3 study to evaluate safusidenib in newly diagnosed grade 2 glioma patients outside the U.S. New Phase 2 study to...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.